Statins May Raise Brain Bleed Risk After Stroke
Adults with a past ischaemic stroke may face slightly higher brain-bleed risk on statins, a UCLA analysis finds.
Updated on Nov. 7, 2026 in Stroke
Live Poll
Would you trust a doctor's advice to switch cholesterol medicines after a stroke?
A UCLA analysis of 36 completed randomised trials found that PCSK9 inhibitors may be a safer cholesterol-lowering option than statins for patients at increased risk of haemorrhagic stroke. The analysis found statins slightly increase haemorrhagic stroke risk in patients who previously had an ischaemic stroke, a group that includes many adults managing cholesterol.
Why it matters
Statins are among the most widely prescribed medicines for cholesterol and stroke prevention, with an estimated 7 to 8 million adults taking them across the UK. The findings matter for prevention decisions because statins reduce the risk of ischaemic stroke while possibly raising the risk of the less common but more dangerous brain bleed, so the balance of benefit may differ by a person's stroke history.
The UCLA analysis pooled data from 36 completed randomised trials, comparing PCSK9 inhibitors and statins. Statins increased haemorrhagic stroke risk slightly in all patients, with higher risk at high doses, while PCSK9 inhibitors lowered cholesterol as strongly as or more strongly than statins.
The players
UCLA
University of California, Los Angeles, the institution that conducted the analysis of completed randomised trials on statins and PCSK9 inhibitors.
The details
Statins block the liver enzyme HMG-CoA reductase, reducing the liver's cholesterol production. In response, the liver pulls more LDL cholesterol out of the bloodstream. Statins lower the risk of ischaemic strokes, which are caused by clots blocking blood flow in the brain, by reducing blood clotting. They do not prevent haemorrhagic strokes, which result from blood vessel rupture rather than clotting, and the analysis suggests they may slightly raise that risk.
Timeline
Research cited in new publications this month after release in Stroke, November 2026.
Health Landscape
Statins remain the standard first-line cholesterol medicine, valued for lowering ischaemic stroke risk across large populations. PCSK9 inhibitors are a newer class of cholesterol-lowering drugs, and this analysis adds haemorrhagic stroke safety data to the comparison between the two.
If you have had a stroke, particularly one caused by a brain bleed, this research is worth raising with your doctor when reviewing your cholesterol treatment. People with a history of stroke should discuss their own risk profile with a clinician before making any changes to their medication.
The takeaway
The key insight is that the stroke-prevention value of statins depends on the type of stroke a person is at risk of. Anyone with a past stroke can ask their physician whether their cholesterol plan accounts for both clot-related and bleed-related stroke risk.
Further reading
For background on the condition at the centre of this research, see our guide to Stroke.
Live Poll
Would you trust a doctor's advice to switch cholesterol medicines after a stroke?
